Cargando…

A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis

BACKGROUND: Patients recruited in randomized controlled trials (RCTs) for biologic therapies in psoriasis are not fully representative of the real‐world psoriasis population. OBJECTIVES: Firstly, to investigate whether patient characteristics are associated with being included in a psoriasis RCT. Se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yiu, Z.Z.N., Mason, K.J., Barker, J.N.W.N., Hampton, P.J., McElhone, K., Smith, C.H., Warren, R.B., Griffiths, C.E.M., Lunt, M., Burden, A.D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916305/ https://www.ncbi.nlm.nih.gov/pubmed/30822358 http://dx.doi.org/10.1111/bjd.17849

Ejemplares similares

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
por: Yiu, Z.Z.N., et al.
Publicado: (2018)

Persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review
por: Mason, K.J., et al.
Publicado: (2019)

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study
por: Rungapiromnan, W., et al.
Publicado: (2019)

Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis
por: Iskandar, I.Y.K., et al.
Publicado: (2017)

Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy
por: Yiu, Z.Z.N., et al.
Publicado: (2019)

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials
por: Rungapiromnan, W., et al.
Publicado: (2017)

Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms
por: Warren, RB, et al.
Publicado: (2009)

Risk of COVID‐19 infection in adult patients with atopic eczema and psoriasis: a single‐centre cross‐sectional study
por: Yiu, Z.Z.N., et al.
Publicado: (2021)

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study
por: Warren, R.B., et al.
Publicado: (2018)

Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)
por: Mahil, S.K., et al.
Publicado: (2019)

Antibody responses to single‐dose SARS‐CoV‐2 vaccination in patients receiving immunomodulators for immune‐mediated inflammatory disease
por: Al‐Janabi, A., et al.
Publicado: (2021)

Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
por: Iskandar, Ireny Y.K., et al.
Publicado: (2018)

Polymorphisms in the PTPN22 region are associated with psoriasis of early onset
por: Smith, RhLl, et al.
Publicado: (2008)

Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register
por: Yiu, Zenas Z. N., et al.
Publicado: (2020)

Double-blind, placebo-controlled pilot trial of L-Leucine-enriched amino-acid mixtures on body composition and physical performance in men and women aged 65–75 years
por: Ispoglou, T, et al.
Publicado: (2016)

Giant condylomata acuminata of Buschke and Lowenstein: A peristomal variant
por: Yiu, Z.Z.N., et al.
Publicado: (2014)

Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis
por: Warren, R.B., et al.
Publicado: (2019)

Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
por: Yiu, Zenas Z.N., et al.
Publicado: (2018)

Treatment of severe psoriasis with infliximab
por: Leman, JA, et al.
Publicado: (2008)

Psoriasis, COVID‐19 and shielding
por: Becher, G., et al.
Publicado: (2021)

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
por: Al-Janabi, A, et al.
Publicado: (2022)

Psoriasis and other complex trait dermatoses: from loci to functional pathways
por: Capon, Francesca, et al.
Publicado: (2011)

Risk‐mitigating behaviours in people with inflammatory skin and joint disease during the COVID‐19 pandemic differ by treatment type: a cross‐sectional patient survey(*)
por: Mahil, S.K., et al.
Publicado: (2021)

Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis
por: Yiu, Zenas Z.N., et al.
Publicado: (2016)

Primary care‐based screening for cardiovascular risk factors in patients with psoriasis
por: Rutter, M.K., et al.
Publicado: (2016)

Anakinra for palmoplantar pustulosis: results from a randomized, double‐blind, multicentre, two‐staged, adaptive placebo‐controlled trial (APRICOT)
por: Cro, S., et al.
Publicado: (2021)

Recovery of Degraded-Beyond-Recognition 19(th) Century Daguerreotypes with Rapid High Dynamic Range Elemental X-ray Fluorescence Imaging of Mercury L Emission
por: Kozachuk, Madalena S., et al.
Publicado: (2018)

Author Correction: Recovery of Degraded-Beyond-Recognition 19(th) Century Daguerreotypes with Rapid High Dynamic Range Elemental X-ray Fluorescence Imaging of Mercury L Emission
por: Kozachuk, Madalena S., et al.
Publicado: (2018)

Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis
por: Jabbar-Lopez, Zarif K., et al.
Publicado: (2017)

Safety of selective IL‐23p19 inhibitors for the treatment of psoriasis
por: Crowley, J.J., et al.
Publicado: (2019)

Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study
por: Phan, Duc Binh, et al.
Publicado: (2023)

How Political Science Can Contribute to Public Health: A Response to Gagnon and Colleagues
por: Kothari, Anita, et al.
Publicado: (2017)

Impact of Copy Neutral Loss of Heterozygosity and Total Genome Aberrations on Survival in Myelodysplastic Syndrome
por: Yeung, Cecilia, et al.
Publicado: (2017)

Twelve‐week secukinumab treatment is consistently efficacious for moderate‐to‐severe psoriasis regardless of prior biologic and non‐biologic systemic treatment: Post hoc analysis of six randomised trials
por: Hampton, P., et al.
Publicado: (2021)

A unifying molecular mechanism underlying the association of CARD14 alleles with autoinflammatory and T-cell mediated skin disorders
por: Berki, D, et al.
Publicado: (2015)

Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis
por: Thorneloe, R.J., et al.
Publicado: (2016)

A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial
por: Cro, Suzie, et al.
Publicado: (2020)

Update on psoriasis immunopathogenesis and targeted immunotherapy
por: Mahil, Satveer K., et al.
Publicado: (2015)

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom
por: Warren, R.B., et al.
Publicado: (2018)

Development of clinical diagnostic criteria for plaque psoriasis in children: an electronic Delphi consensus study with the International Psoriasis Council
por: Burden‐Teh, E., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_687oks1cmt596o1fcipqr5r7fs